IDO in Colorectal Tumorigenesis: Involvement of Immune Tolerance and Significance in Prevention and Therapy
Shunan Tang,Jingya Wang,Siwang Yu
DOI: https://doi.org/10.1016/j.jcmgh.2021.06.021
2021-01-01
Abstract:Colorectal cancer (CRC) ranks third in incidence and second in mortality worldwide,1Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin. 2021; 71: 209-249Crossref PubMed Scopus (9275) Google Scholar and the incidence rates have been increasing in less developed regions and in younger individuals in many developed countries.2Siegel R.L. Miller K.D. Goding Sauer A. Fedwa S.A. Butterfly L.F. Anderson J.C. Cercek A. Smith R.A. Jemal A. Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164Crossref PubMed Scopus (1449) Google Scholar Despite the significant improvements in primary prevention, screening, and to a lesser extent, treatment,2Siegel R.L. Miller K.D. Goding Sauer A. Fedwa S.A. Butterfly L.F. Anderson J.C. Cercek A. Smith R.A. Jemal A. Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164Crossref PubMed Scopus (1449) Google Scholar the prognosis of patients with metastatic colorectal cancer (mCRC) remains poor.3Ganesh K. Stadler Z.K. Cercek A. Mendelsohn R.B. Shia J. Segal N.H. Diaz Jr., L.A. Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol. 2019; 16: 361-375Crossref PubMed Scopus (406) Google Scholar Recently, immune checkpoint inhibitors (ICIs) demonstrated exciting efficacy in CRC characterized by mismatch repair (MMR)–deficient or high levels of microsatellite instability (MSI) in multiple clinical trials, and pembrolizumab, nivolumab, and the combination of nivolumab and ipilimumab have been approved by the U.S. Food and Drug Administration for treatment of MMR-deficient/high MSI CRCs.3Ganesh K. Stadler Z.K. Cercek A. Mendelsohn R.B. Shia J. Segal N.H. Diaz Jr., L.A. Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol. 2019; 16: 361-375Crossref PubMed Scopus (406) Google Scholar However, the majority of CRC (85%) and mCRC (95%) cases are MMR-proficient or MSI low and are essentially nonresponsive to ICIs.3Ganesh K. Stadler Z.K. Cercek A. Mendelsohn R.B. Shia J. Segal N.H. Diaz Jr., L.A. Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol. 2019; 16: 361-375Crossref PubMed Scopus (406) Google Scholar Other potential immunotherapies and combinations, including ICIs other than inhibitors of PD-1/PD-L1 or CTLA-4, are under active pursuing. IDO is one of the well-recognized immune suppressive molecules. Both IDO and TDO catalyze the rate-limiting cleavage of essential amino acid tryptophan (Trp) into kynurenine (Kyn) pathway, resulting in depletion of Trp and production of immunoregulatory molecules including Kyn. While TDO exists mainly in liver and brain, IDO, specifically IDO1, is expressed in certain endothelial and epithelial cells in response to certain pathological conditions such as inflammation and cancer.4Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.Eur J Pharmacol. 2021; 896: 173921Crossref PubMed Scopus (10) Google Scholar High IDO expression in CRC is associated with immune tolerance, metastasis, and poor prognosis, and increased serum Kyn-to-Trp ratio could serve as a screening marker of CRC.4Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.Eur J Pharmacol. 2021; 896: 173921Crossref PubMed Scopus (10) Google Scholar Kyn is an agonist of aromatic hydrocarbon receptor (AhR), which induces differentiation of regulatory T (Treg) cells and the expression of PD-1 in CD8+ T cells,4Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.Eur J Pharmacol. 2021; 896: 173921Crossref PubMed Scopus (10) Google Scholar and intestinal epithelial loss of AhR enhanced cecum and colon tumorigenesis.5Han H. Davidson L.A. Hensel M. Yoon G. Landrock K. Allred C. Jayaraman A. Ivanov I. Safe S.H. Chapkin R.S. Loss of aryl hydrocarbon receptor promotes colon tumorigenesis in Apc(S580/+); Kras(G12D/+) mice.Mol Cancer Res. 2021; 19: 771-783Crossref PubMed Scopus (4) Google Scholar Mechanistically, IDO and its Kyn pathway metabolites have been reported to activate β-catenin and PI3K-Akt signaling pathways to promote cancer cell proliferation and inhibit apoptosis and thus facilitate colon tumorigenesis.6Bishnupuri K.S. Alvarado D.M. Khouri A.N. Shabsovich M. Chen B. Dieckgraefe B.K. Ciorbia M.A. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis.Cancer Res. 2019; 79: 1138-1150Crossref PubMed Scopus (62) Google Scholar,7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar However, the involvement of IDO in immune tolerance, which has been well characterized in other cancers and is more relevant to immunotherapy efficacy, has not been determined in CRC, and the exact mechanisms by which IDO regulates the fate of immune cells in colorectal tumor microenvironment remain unknown. In this issue of Cellular and Molecular Gastroenterology and Hepatology, Zhang et al8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar carefully examined the impact of activated IDO in colon cancer cells on T cells and mice spleen lymphocytes using conditioned medium from IDO-activated colon cancer cells, then validated their findings using azoxymethane (AOM)/dextran sodium sulfate (DSS)–induced colitis-associated cancer (CAC) model in IDO–/–, Rag1–/–, and wild-type mice.8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar The conditioned medium inhibited proliferation of activated T cells (Jurkat cells) by cell cycle arrest, and promoted transdifferentiation of mice spleen lymphocytes into FoxP3+ Treg cells instead of CD8+ T cells, in a Trp-independent, AhR-dependent, and Kyn-like manner. These results not only confirmed the immune-suppressive effects of IDO activation in CRC, but also provided new mechanistic interpretation of the previously documented IDO-mediated increase of Treg cells in CRC mice models.9Takamatsu M. Hirata A. Ohtaki H. Hoshi M. Ando T. Ito H. Hatano Y. Tomita H. Kuno T. Saito K. Seishima M. Hara A. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.Cancer Sci. 2015; 106: 1008-1015Crossref PubMed Scopus (37) Google Scholar Previous studies reported that both genetic knockout and pharmacological inhibition of IDO attenuated AOM/DSS-induced mice colon tumorigenesis, while the involvement of adaptive immune response was excluded.6Bishnupuri K.S. Alvarado D.M. Khouri A.N. Shabsovich M. Chen B. Dieckgraefe B.K. Ciorbia M.A. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis.Cancer Res. 2019; 79: 1138-1150Crossref PubMed Scopus (62) Google Scholar,7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar Zhang et al8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar demonstrated similar phenotypic results in the present article and their previous publication.10Liu X. Zhou W. Zhang X. Ding Y. Du Q. Hu R. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells.Int J Cancer. 2018; 143: 1516-1529Crossref PubMed Scopus (23) Google Scholar Interestingly, decreased Treg cells and increased CD8+ T cells were detected in tumors of IDO–/– CAC mice, while Kyn treatment significantly counteracted the effects of IDO deficiency, suggesting an important role of IDO-Kyn-AhR-FoxP3–mediated immune-suppressive environment in colon tumorigenesis. It is noteworthy that the role of AhR in colon tumorigenesis has been controversial, and it has also been recognized as a tumor suppressor.5Han H. Davidson L.A. Hensel M. Yoon G. Landrock K. Allred C. Jayaraman A. Ivanov I. Safe S.H. Chapkin R.S. Loss of aryl hydrocarbon receptor promotes colon tumorigenesis in Apc(S580/+); Kras(G12D/+) mice.Mol Cancer Res. 2021; 19: 771-783Crossref PubMed Scopus (4) Google Scholar,11Campesato L.F. Budhu S. Tchaicha J. Went C.-H. Gigoux M. Cohen I.J. Redmond D. Mangarin L. Pourpe S. Liu C. Zappasodi R. Zamarin D. Cavanaugh J. Castro A.C. Manfredi M.G. McGovern K. Merghoub T. Wolchok J.D. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.Nat Commun. 2020; 11: 4011Crossref PubMed Scopus (60) Google Scholar Such controversary might result from the complexity and plasticity of AhR signaling,12Leclerc D. Staats Pires A.C. Guillemin G.J. Gilot D. Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies.Curr Opin Immunol. 2021; 70: 15-26Crossref PubMed Scopus (13) Google Scholar and thus AhR may not be a good target candidate of immunotherapies. On the other hand, Rag1–/– mice without mature T and B cells were more susceptible to AOM/DSS-induced CAC, which further supports the importance of T cells in colon carcinogenesis. Surprisingly, IDO deficiency in a Rag1–/– background (IDO–/–::Rag–/– mice) also inhibited AOM/DSS-induced CAC,7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar suggesting that further investigations are guaranteed. Among the known immune checkpoint molecules, IDO is the only one that can be targeted by small molecules. Therefore, IDO inhibitors are of special interest to medicinal chemists and pharmaceutical industry. IDO inhibitors or in combination with anti-PD-1/PD-L1 therapies have been extensively investigated in various cancers, and very promising results have been obtained in preclinical and early phase clinical investigations. Unfortunately, the enthusiasm has been greatly dampened by lack of efficacy in recent clinical trials.13Companies Scaling Back IDO1 Inhibitor Trials.Cancer Discov. 2018; 8: OF5Crossref Scopus (11) Google Scholar However, as suggested by Zhang et al8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar,10Liu X. Zhou W. Zhang X. Ding Y. Du Q. Hu R. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells.Int J Cancer. 2018; 143: 1516-1529Crossref PubMed Scopus (23) Google Scholar and others,14Fletcher R. Wang Y.J. Schoen R.E. Finn O.J. Yu J. Zhang L. Colorectal cancer prevention: Immune modulation taking the stage.Biochim Biophys Acta Rev Cancer. 2018; 1869: 138-148Crossref PubMed Scopus (41) Google Scholar IDO inhibitors may find a better avenue in prevention of CRC. Indeed, the inducible expression of IDO by inflammatory stimuli is especially interesting for colorectal carcinogenesis, as inflammatory bowel diseases are well recognized as a risk factor of CRC.2Siegel R.L. Miller K.D. Goding Sauer A. Fedwa S.A. Butterfly L.F. Anderson J.C. Cercek A. Smith R.A. Jemal A. Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164Crossref PubMed Scopus (1449) Google Scholar Chemoprevention of CRC by anti-inflammatory drugs such as celecoxib and aspirin has been successful. Although inhibition of IDO may augment colitis,15Gurtner G.J. Newberry R.D. Schloemann S.R. McDonald K.G. Stenson W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice.Gastroenterology. 2003; 125: 1762-1773Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar Thaker et al7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar proved that such an effect was dependent on the severity of colitis. IDO inhibitors, at the crossroad of chemoprevention and immunoprevention, definitely deserve further investigation as a preventive agent of CRC or therapy of precancerous colorectal lesions. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune ToleranceCellular and Molecular Gastroenterology and HepatologyVol. 12Issue 4PreviewChronic inflammation in colon section is associated with an increased risk of colorectal cancer (CRC). Proinflammatory cytokines were produced in a tumor microenvironment and correlated with poor clinical outcome. Tumor-infiltrating T cells were reported to be greatly involved in the development of colon cancer. In this study, we demonstrated that kynurenine (Kyn), a metabolite catalyzed by indoleamine 2,3-dioxygenase (IDO), was required for IDO-mediated T cell function, and adaptive immunity indeed played a critical role in CRC. Full-Text PDF Open Access